黑料网

Oxygen; Hypoxia; HIF signaling pathway; Oxygen metabolism; Immune cells; Innate immune responses; Adoptive immune responses

Introduction

In the intricate landscape of human physiology, the relationship between hypoxia, metabolism, and immune cell function represents a captivating nexus of biological processes. Hypoxia, or oxygen deficiency, profoundly impacts cellular metabolism and consequently influences the behavior and function of immune cells. This article delves into the intricate interplay between these elements, shedding light on how hypoxia shapes metabolic pathways and modulates immune responses [1].

Hypoxia and cellular metabolism

At the cellular level, oxygen serves as a critical substrate for oxidative phosphorylation, the primary pathway for generating adenosine triphosphate (ATP), the energy currency of cells. Hypoxia disrupts this process, forcing cells to adapt their metabolic strategies to maintain energy homeostasis. In response to low oxygen levels, cells undergo a metabolic shift characterized by increased glycolysis, even in the presence of oxygen-a phenomenon known as the Warburg effect [2]. This metabolic reprogramming allows cells to sustain ATP production under hypoxic conditions but comes at the cost of decreased efficiency compared to oxidative phosphorylation.

Immune cell responses to hypoxia

Immune cells, including macrophages, T cells, and dendritic cells, are highly sensitive to changes in oxygen levels within their microenvironment. Hypoxia alters the phenotype and function of immune cells, influencing their recruitment, activation, and effector functions. For instance, hypoxia promotes the differentiation of naïve T cells into regulatory T cells (Tregs), which play a crucial role in immune tolerance and suppression of excessive immune responses. Additionally, hypoxia enhances the production of pro-inflammatory cytokines by macrophages and T cells, contributing to the immune response against pathogens or tumors.

Metabolic regulation of immune cell function

Metabolism lies at the core of immune cell activation and effector functions. Upon activation, immune cells undergo metabolic reprogramming to meet the increased energetic and biosynthetic demands associated with their effector functions. For example, effector T cells primarily rely on glycolysis to support rapid proliferation and cytokine production. Conversely, memory T cells exhibit a more oxidative metabolism, enabling long-term survival and rapid recall responses upon reactivation [3-5]. Moreover, metabolic intermediates, such as succinate and itaconate, serve as signaling molecules that influence immune cell function and inflammatory responses.

Hypoxia, characterized by insufficient oxygen levels in tissues, exerts profound effects on cellular physiology and function. Among the diverse array of cells affected by hypoxia, myeloid cells, including macrophages, dendritic cells, and neutrophils, play pivotal roles in immune regulation, inflammation, and tissue homeostasis. This article explores the intricate relationship between hypoxia and myeloid cell function, with a specific focus on metabolic adaptations that underlie immune responses in hypoxic microenvironments.

Hypoxia sensing and response in myeloid cells

Myeloid cells possess sophisticated mechanisms to sense and respond to changes in oxygen availability. Central to this response is the hypoxia-inducible factor (HIF) pathway, comprising oxygen-sensitive HIF-α subunits and constitutively expressed HIF-β subunits. Under normoxic conditions, prolyl hydroxylase domain proteins (PHDs) hydroxylate HIF-α subunits, marking them for ubiquitination and proteasomal degradation. However, under hypoxic conditions, PHD activity is inhibited, leading to the stabilization and accumulation of HIF-α subunits, which translocate to the nucleus and dimerize with HIF-β subunits to activate transcription of target genes involved in angiogenesis, erythropoiesis, and metabolism [6].

Metabolic reprogramming in hypoxic myeloid cells

Hypoxia induces metabolic reprogramming in myeloid cells, driving shifts in glucose, lipid, and amino acid metabolism to meet the energetic and biosynthetic demands associated with immune responses. Notably, hypoxia promotes glycolysis in myeloid cells, facilitating ATP production and providing metabolic intermediates for biosynthetic pathways. Moreover, hypoxic myeloid cells exhibit altered lipid metabolism, with increased fatty acid uptake and oxidation to sustain cellular functions. Additionally, hypoxia influences amino acid metabolism, modulating the production of metabolites involved in redox balance, signaling, and immune regulation.

Impact on immune cell function and inflammation

The metabolic adaptations driven by hypoxia profoundly influence the function and phenotype of myeloid cells, shaping immune responses and inflammatory processes. Hypoxic myeloid cells exhibit enhanced phagocytic activity, cytokine production, and antigen presentation, contributing to host defense against pathogens and tumors. Furthermore, hypoxia-driven metabolic reprogramming promotes the polarization of macrophages toward pro-inflammatory or anti-inflammatory phenotypes, influencing the resolution or exacerbation of inflammatory responses.

Implications for disease pathogenesis and therapy

Dysregulated hypoxia responses and metabolic alterations in myeloid cells are implicated in the pathogenesis of various diseases, including cancer, autoimmune disorders, and chronic inflammatory conditions. Targeting metabolic pathways and the HIF signaling pathway in myeloid cells emerges as a promising therapeutic strategy for modulating immune responses and improving clinical outcomes in these diseases. Furthermore, understanding the complex interplay between hypoxia, metabolism, and myeloid cell function holds the potential to uncover novel biomarkers and therapeutic targets for precision medicine approaches [7].

Implications for health and disease

The intricate interplay between hypoxia, metabolism, and immune cell function has significant implications for human health and disease. Dysregulated hypoxic responses and metabolic alterations contribute to the pathogenesis of various diseases, including cancer, autoimmune disorders, and chronic inflammatory conditions [8]. Targeting metabolic pathways and the hypoxia-inducible factor (HIF) signaling pathway has emerged as a promising therapeutic strategy for modulating immune responses and improving clinical outcomes in these diseases.

Conclusion

In summary, the dynamic interplay between hypoxia, metabolism, and immune cell function orchestrates the body's response to physiological and pathological challenges. Understanding these complex interactions not only deepens our knowledge of fundamental biological processes but also unveils novel therapeutic avenues for treating a spectrum of diseases. Future research endeavors aimed at deciphering the intricacies of this triad hold the potential to revolutionize immunotherapy and precision medicine, ushering in a new era of personalized healthcare. hypoxia exerts multifaceted effects on myeloid cell function and metabolism, influencing immune responses, inflammation, and disease pathogenesis. Elucidating the molecular mechanisms underlying hypoxia-induced metabolic reprogramming in myeloid cells offers insights into the dynamic interplay between cellular metabolism and immune regulation. Harnessing this knowledge may pave the way for innovative therapeutic interventions and personalized treatment strategies in a variety of pathological conditions characterized by dysregulated immune responses.

References

1. Baskaran N, Manoharan S, Balakrishnan S, Pugalendhi P (2010). Eur J Pharmaco 63: 22.

, ,

2. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2021).Nature 486: 346–352.

, ,

3. Sharmila R, Manoharan S (2012). Ind J of Physio Sciences 7: 344-356.

,

4. Sivaramakrishna R, Gordon R (2022). Acad Radiol 4: 8–12.

, ,

5. Suresh S, Manoharan M, Vijayaanand P, Sugunadevi A (2020)Pharmacological Reports 62: 1178–1185.

, ,

6. Michaelson JS, Silverstein M, Wyatt J (2017) Cancer 95: 713–723.

, ,

7. Anjugam C, Sridevi N, Rajendra Prasad M, Balupillai A (2018). Asian J Pharma Clin Res 11: 24-34.

, ,

8. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. (2020).Nature 486: 400–404.

, ,